Anthony Sandoval, MD
Cardiovascular Disease · Flagstaff, AZNPI 1811994429
Payments from drug & device makers
Across 137 payments — averaging $38.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$971
- Amgen$371
- Abbott$370
- E.r. Squibb & Sons, L.L.C.$362
- Boston Scientific$345
- Edwards Lifesciences$289
- plus $3K from 25 others
What the payments were for
- Food & beverage$5,26599%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 15 | $971 |
| Amgen | 7 | $371 |
| Abbott | 6 | $370 |
| E.r. Squibb & Sons, L.L.C. | 16 | $362 |
| Boston Scientific | 4 | $345 |
| Edwards Lifesciences | 2 | $289 |
| Medtronic | 4 | $246 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $227 |
| W. L. Gore & Associates, Inc. | 3 | $226 |
| Philips North America LLC | 3 | $225 |
| Novartis | 11 | $203 |
| Pfizer | 9 | $189 |
| Cardiovascular Systems Inc. | 5 | $158 |
| Impulse Dynamics (USA) Inc. | 1 | $154 |
| Biosense Webster, Inc. | 3 | $131 |
| Johnson & Johnson | 6 | $119 |
| ZOLL Circulation Inc | 1 | $103 |
| Merck | 1 | $97 |
| Boehringer Ingelheim | 4 | $94 |
| AstraZeneca | 6 | $88 |
| Regeneron Healthcare Solutions, Inc. | 6 | $81 |
| Terumo Medical Corporation | 1 | $63 |
| Bardy Diagnostics, Inc. | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Cordis US CORP. | 1 | $27 |
| Stryker | 1 | $25 |
| Teleflex LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Bayer | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$679
- Repatha$224
- Edwards SAPIEN 3 Transcatheter Heart Valve$182
- AMPLATZER$164
- OPTIMIZER$154
- Optis Coronary Imaging System$130
- CAMZYOS$122
- GENERAL - THERAPIES$119
- IGT D Coronary$116
- GORE CARDIOFORM Septal Occluder$114
- RESOLUTE ONYX$108
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$107
- TherOx DS2 Console$103
- Catheter$103
- Downstream Cartridge$103
How this compares
$5,323 in reported general payments places this provider in the 60th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $125,520 |
| BrilintaTicagrelor | 24 | $26,319 |
| EntrestoSacubitril/Valsartan | 31 | $25,050 |
| XareltoRivaroxaban | 28 | $21,020 |
| VascepaIcosapent Ethyl | 12 | $4,179 |
| Metoprolol Succinate | 259 | $3,246 |
| Ranolazine ErRanolazine | 24 | $2,408 |
| Losartan Potassium | 114 | $1,378 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 27 | $1,157 |
| Nebivolol Hcl | 27 | $1,155 |
| Olmesartan Medoxomil | 41 | $1,138 |
| Atorvastatin Calcium | 108 | $1,134 |
| Rosuvastatin Calcium | 67 | $1,052 |
| Amiodarone Hcl | 17 | $1,020 |
| Amlodipine Besylate | 131 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $189 | $125,520121 claims |
| AstraZenecaBrilinta | $88 | $26,31924 claims |
| NovartisEntresto | $203 | $25,05031 claims |
| Johnson & JohnsonXarelto | $119 | $21,02028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Flagstaff
- Omar WaniFlagstaff$295K
- Christopher MuellerFlagstaff$105K
- David RizikScottsdale$2.1M
- Rodrigo ChanMesa$2M
- Ashish GuptaPhoenix$1.2M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Gregory KoshkarianTucson$608K
- Andrew KaplanMesa$455K
- Charles JostMesa$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.